<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04002089</url>
  </required_header>
  <id_info>
    <org_study_id>402-C-122</org_study_id>
    <nct_id>NCT04002089</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety, of EXPAREL Administered as Sciatic Nerve Block (In Popliteal Fossa), for Postsurgical Analgesia in Subjects Undergoing Bunionectomy</brief_title>
  <official_title>A Phase 1, Pilot, Open Label, Dose Escalation Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety, of EXPAREL Administered as Sciatic Nerve Block (In Popliteal Fossa), for Postsurgical Analgesia in Subjects Undergoing Bunionectomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pacira Pharmaceuticals, Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pacira Pharmaceuticals, Inc</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a pilot, open label, single center study in 40 subjects undergoing bunionectomy. The&#xD;
      study will assess and collect information on pharmacokinetics, pharmacodynamics, safety and&#xD;
      efficacy of EXPAREL administered as a sciatic nerve block (in popliteal fossa).&#xD;
&#xD;
      A total of 10 subjects will be enrolled in each of the 4 cohorts.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 26, 2019</start_date>
  <completion_date type="Actual">December 2, 2019</completion_date>
  <primary_completion_date type="Actual">December 2, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetic 1 (Area under the plasma concentration)</measure>
    <time_frame>predose (up to 15 min before block), 30 min(±5min), 45 min(±5min), and 60 min (±15min) and 30 min(±5min), 45 min(±5min), 1(±15min), 2(±30min), 12(±30min), 24(±1), 60(±2), 72(±2), 84(±2), 96(±3), 120(±3), 144(±3), and 168(±3) hours following block</time_frame>
    <description>Area under the plasma concentration-versus-time curve (AUC).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic 2 (Cmax)</measure>
    <time_frame>predose (up to 15 min before block), 30 min(±5min), 45 min(±5min), and 60 min (±15min) and 30 min(±5min), 45 min(±5min), 1(±15min), 2(±30min), 12(±30min), 24(±1h), 60(±2h), 72(±2h), 84(±2h), 96(±3h), 120(±3h), 144(±3h), and 168(±3h) hours following block</time_frame>
    <description>Maximum plasma concentration (Cmax)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic 3 (half-life )</measure>
    <time_frame>predose (up to 15 min before block), 30 min(±5min), 45 min(±5min), and 60 min (±15min) and 30 min(±5min), 45 min(±5min), 1(±15min), 2(±30min), 12(±30min), 24(±1h), 60(±2h), 72(±2h), 84(±2h), 96(±3h), 120(±3h), 144(±3h), and 168(±3h) hours following block</time_frame>
    <description>The apparent terminal elimination half-life (t1/2el).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic 4 (Apparent clearance)</measure>
    <time_frame>predose (up to 15 min before block), 30 min(±5min), 45 min(±5min), and 60 min (±15min) and 30 min(±5min), 45 min(±5min), 1(±15min), 2(±30min), 12(±30min), 24(±1h), 60(±2h), 72(±2h), 84(±2h), 96(±3h), 120(±3h), 144(±3h), and 168(±3h) hours following block</time_frame>
    <description>Apparent clearance (CL/F).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic 5 (volume of distribution)</measure>
    <time_frame>predose (up to 15 min before block), 30 min(±5min), 45 min(±5min), and 60 min (±15min) and 30 min(±5min), 45 min(±5min), 1(±15min), 2(±30min), 12(±30min), 24(±1h), 60(±2h), 72(±2h), 84(±2h), 96(±3h), 120(±3h), 144(±3h), and 168(±3h) hours following block</time_frame>
    <description>Apparent volume of distribution (Vd).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic 6 (Tmax)</measure>
    <time_frame>predose (up to 15 min before block), 30 min(±5min), 45 min(±5min), and 60 min (±15min) and 30 min(±5min), 45 min(±5min), 1(±15min), 2(±30min), 12(±30min), 24(±1h), 60(±2h), 72(±2h), 84(±2h), 96(±3h), 120(±3h), 144(±3h), and 168(±3h) hours following block</time_frame>
    <description>Time of Cmax (Tmax)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacodynamic 1 (duration of sensory and motor block)</measure>
    <time_frame>up to 15 min before block, 15 min(±5 min), 30 min(±5min), 45 min(±5min), and 60 min (±15min) and 30 min(±5min), 45 min(±5min), 1(±15min), 2(±30min), 12(±30min), 24(±1), 60(±2), 72(±2), 84(±2), 96(±3), 120(±3), 144(±3), and 168(±3) hours following block</time_frame>
    <description>Average duration of sensory block and motor block</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacodynamic 2 (duration of sensory and motor block)</measure>
    <time_frame>up to 15 min before block, 15 min(±5min), 30 min(±5min), 45 min(±5min), and 60 min (±15min) and 30 min(±5min), 45 min(±5min), 1(±15min), 2(±30min), 12(±30min), 24(±1), 60(±2), 72(±2), 84(±2), 96(±3), 120(±3), 144(±3), and 168(±3) hours following block</time_frame>
    <description>Average duration of sensory block and motor block</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">45</enrollment>
  <condition>Bunion</condition>
  <arm_group>
    <arm_group_label>Cohort 1 - EXPAREL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A total of 10 subjects will be enrolled. Subjects in this cohort will receive 266mg of EXPAREL admixed with bupivacaine.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2 - EXPAREL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A total of 10 subjects will be enrolled. Subjects in this cohort will receive 133mg of EXPAREL admixed with bupivacaine.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3 - EXPAREL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A total of 10 subjects will be enrolled. Subjects in this cohort will receive 266mg of EXPAREL only</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4 - bupivacaine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>A total of 10 subjects will be enrolled. Subjects in this cohort will receive 100mg Bupivacaine only.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Exparel Injectable Product</intervention_name>
    <description>bupivacaine liposome injectable suspension</description>
    <arm_group_label>Cohort 1 - EXPAREL</arm_group_label>
    <arm_group_label>Cohort 2 - EXPAREL</arm_group_label>
    <arm_group_label>Cohort 3 - EXPAREL</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bupivacaine</intervention_name>
    <description>1.3%, 13.3 mg/mL</description>
    <arm_group_label>Cohort 1 - EXPAREL</arm_group_label>
    <arm_group_label>Cohort 2 - EXPAREL</arm_group_label>
    <arm_group_label>Cohort 4 - bupivacaine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Healthy adult male or female volunteers ages 18 or older&#xD;
&#xD;
          2. American Society of Anesthesiologists (ASA) physical status 1, 2, or 3&#xD;
&#xD;
          3. Able to provide informed consent, adhere to the study schedule, and complete all study&#xD;
             assessments.&#xD;
&#xD;
          4. Body Mass Index ≥18 and ≤40 kg/m2&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Allergy, hypersensitivity, intolerance, or contraindication to any of the study&#xD;
             medications for which an alternative is not named in the protocol (eg, amide-type&#xD;
             local anesthetics, opioids, bupivacaine, NSAIDs)&#xD;
&#xD;
          2. Documented history of long-term diabetes or severe peripheral vascular disease&#xD;
&#xD;
          3. Renal (serum creatinine level &gt;2mg/dL [176.8 μmol/L]) or hepatic dysfunction (serum&#xD;
             alanine or aspartame transferase &gt; 3 times the upper limit of normal).&#xD;
&#xD;
          4. Concurrent painful physical condition that may require analgesic treatment (such as&#xD;
             long-term, consistent use of opioids) in the post dosing period for pain and which, in&#xD;
             the investigator's opinion may confound the post dosing assessments&#xD;
&#xD;
          5. History of, suspected, or known addiction to or abuse of illicit drug(s), prescription&#xD;
             medicine(s), or alcohol within the past 2 years&#xD;
&#xD;
          6. Administration of an investigational drug within 30 days or 5 elimination half-lives&#xD;
             of such investigational drug, whichever is longer, prior to study drug administration,&#xD;
             or planned administration of another investigational product or procedure during the&#xD;
             subject's participation in this study&#xD;
&#xD;
          7. Previous participation in an EXPAREL study&#xD;
&#xD;
          8. Uncontrolled anxiety, schizophrenia, or other psychiatric disorder that, in the&#xD;
             opinion of the investigator, could interfere with study assessments or compliance&#xD;
&#xD;
          9. Currently pregnant, nursing, or planning to become pregnant during the study&#xD;
&#xD;
         10. Clinically significant medical disease that, in the opinion of the investigator, would&#xD;
             make participation in a clinical study inappropriate. This includes any psychiatric or&#xD;
             other conditions that would constitute a contraindication to participation in the&#xD;
             study&#xD;
&#xD;
         11. Currently on neuroleptic agent [e.g., gabapentin, pregabalin (Lyrica), duloxetine&#xD;
             (Cymbalta) etc.]&#xD;
&#xD;
         12. Inadequate sensory function on the foot (monofilament test)&#xD;
&#xD;
         13. Chronic opioid use in the last 30 days (≥30 morphine equivalents/ day)&#xD;
&#xD;
             In addition, the subject may be withdrawn from the study if the subject meets the&#xD;
             following criterion during or post-surgery:&#xD;
&#xD;
         14. Any clinically significant event or condition uncovered during the surgery (e.g.,&#xD;
             excessive bleeding, acute sepsis) that, in the opinion of the investigator, renders&#xD;
             the subject medically unstable or complicates the subject's post-operative course&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nayana Nagaraj</last_name>
    <role>Study Director</role>
    <affiliation>Medical Director</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>First Surgical Hospital</name>
      <address>
        <city>Bellaire</city>
        <state>Texas</state>
        <zip>77401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>June 25, 2019</study_first_submitted>
  <study_first_submitted_qc>June 26, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 28, 2019</study_first_posted>
  <last_update_submitted>January 7, 2021</last_update_submitted>
  <last_update_submitted_qc>January 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bunion</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bupivacaine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

